4//SEC Filing
PERRY GREGORY D 4
Accession 0001193125-25-317968
CIK 0001651311other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:09 PM ET
Size
27.0 KB
Accession
0001193125-25-317968
Insider Transaction Report
Form 4
Merus N.V.MRUS
PERRY GREGORY D
Chief Financial Officer & PFO
Transactions
- Disposition to Issuer
Share Option (right to buy)
2025-12-12−100,000→ 0 totalExercise: $41.65Exp: 2035-01-29→ Common Shares (100,000 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−107,300→ 0 totalExercise: $36.09Exp: 2034-01-31→ Common Shares (107,300 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−372,924→ 0 totalExercise: $26.50Exp: 2033-06-14→ Common Shares (372,924 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−14,414→ 0 totalExercise: $23.29Exp: 2033-06-08→ Common Shares (14,414 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−16,604→ 0 totalExercise: $18.56Exp: 2032-05-31→ Common Shares (16,604 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−6,120→ 0 totalExercise: $21.15Exp: 2031-05-28→ Common Shares (6,120 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−8,631→ 0 totalExercise: $16.09Exp: 2030-06-30→ Common Shares (8,631 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−17,000→ 0 totalExercise: $10.04Exp: 2026-05-18→ Common Shares (17,000 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−5,650→ 0 totalExercise: $19.12Exp: 2027-05-24→ Common Shares (5,650 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−4,983→ 0 totalExercise: $23.30Exp: 2028-07-20→ Common Shares (4,983 underlying) - Disposition to Issuer
Share Option (right to buy)
2025-12-12−8,500→ 0 totalExercise: $13.35Exp: 2029-06-12→ Common Shares (8,500 underlying)
Footnotes (2)
- [F1]On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
- [F2]This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Documents
Issuer
Merus N.V.
CIK 0001651311
Entity typeother
Related Parties
1- filerCIK 0001236371
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 7:09 PM ET
- Size
- 27.0 KB